The Italian Journal of Neurological Sciences

, Volume 5, Issue 4, pp 413–416 | Cite as

Neuroendocrinological study of opioid and serotoninergic systems in migraine patients

  • Bussone G. 
  • Boiardi A. 
  • Mantia L. La 
  • Frediani F. 
  • Martini A. 
  • Giulio A. M. Di 
  • Panerai A. E. 
Original Articles
  • 23 Downloads

Abstract

PRL response to morphine in a group of migraine subjects was studied in the baseline condition and after neuroendocrinological inhibition and stimulation tests. No significant differences were found in comparison with control subjects. This demonstrated the integrity of the opioid system and serotoninergic pathways in migraine subjects.

Key-words

Migraine morphine serotonin naloxone prolactin 

Sommario

In un gruppo di soggetti emicranici è stata studiata la risposta in prolattina alla morfina in condizioni basali e con tests neuroendocrinologici di stimolazione ed inibizione.

Non si sono riscontrate significative differenze nei confronti dei soggetti di controllo.

Si è cosi documentata l'integrità del sistema degli oppiati endogeni e della via serotoninergica nei pazienti emicranici.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Ad Hoc Committee on Classification of Headache. JAMA 179: 717–718, 1962Google Scholar
  2. [2]
    Beretta C., Ferrini R., Glasser A.H.:1.6-Dimethyl-8-betacarbobenzyl-oxy-aminomethyl-10-alpha-ergoline, a potent long-lasting 5-Hydroxytryptamine antagonist. Nature 207: 421–422, 1965PubMedGoogle Scholar
  3. [3]
    Blumberg H., Dayton H.B.:Naloxone and related compounds. In: Agonist and Antagonist Actions of Narcotic Analgesic Drugs, p. 110 Kosterlitz et al., University Park Press, Baltimore, 1974Google Scholar
  4. [4]
    Bruni J.F., Van Vugt D., Marshall S., Meites J.:Effect of naloxone, morphine and methionine enkephalin on serum prolactin, luteinizing hormone, follicle stimulating hormone and growth hormone. Life Sci. 21: 461–466, 1977PubMedGoogle Scholar
  5. [5]
    Carruba M.O., Nisticò G., Mantegazza P.:Evidence for a receptor supersensitivity following impairment of central serotoninergic activity in the rabbit. N.S. Arch. Pharmacol. 309: 125–129, 1979Google Scholar
  6. [6]
    Cheney D.L., Costa E., Hanin I., Racagni G., Trabucchi M.:Acetylcholine turnover rate in brain of mice and rats: effects of various dose regimens of morphine. In: Cholinergic Mechanism, pp. 217–228, Waser, Raven Press, New York, 1975Google Scholar
  7. [7]
    Chiodini G.P., Liuzzi A., Muller E.E., Botalla G., Cremascoli G., Oppizzi G., Verde G., Silvestrini F.:Inhibitory effect of metergoline, an ergoline derivative, on growth hormone and prolactin levels in acromegalic patients. J. Clin. Endocr. Metab. 43: 356–363, 1976PubMedGoogle Scholar
  8. [8]
    Clarenbach P., Del Pozo E., Brownell J., Heredia E., Spiegel R., Cramer H.:Characterization of ergot and non ergot serotonin antagonist and growth hormone peptides during wake-fulness and sleep. Brain Res. 202: 357–363, 1980PubMedGoogle Scholar
  9. [9]
    Fuxe K., Agnati L., Everitt H.B.:Effect of metergoline on central monoamine neurons. Evidence for a selective blockage of central 5-HT receptor. Neurosci. Lett. 1: 283–288, 1975PubMedGoogle Scholar
  10. [10]
    Imura H., Nakaj J., Yoshimi T.:Effects of 5-hydroxy-tryptophan (5-HT) on growth hormone and ACTH release in man. J. Clin. Endocr. Metab. 36: 204–206, 1973PubMedGoogle Scholar
  11. [11]
    Koenig J., Mayfield M.A., Coppings J., McCann S.M., Krulich L.:Role of morphine in growth hormone and prolactin secretion in the rat. Brain Res. 197: 453–468, 1980PubMedGoogle Scholar
  12. [12]
    Yoneda Y., Kuryama K., Kurihana E.:Morphine alters distribution of GABA in Thalamus. Brain Res. 124: 373–378, 1977PubMedGoogle Scholar
  13. [13]
    Muller E.E., Brambilla F., Cavagnini F., Peracchi M., Panerai A.E.:Slight effect of L-Tryptophan on growth hormone release in normal human subjects. J. Clin. Endocr. Metab. 39: 1–5. 1974PubMedGoogle Scholar
  14. [14]
    Muller E.E., Udeschini G., Secchi C., Zambotti F., Panerai A.E., Vicentini L., Cocola F., Mantegazza P.:Inhibitory role of the serotoninergic system in hypoglycaemia-induced growth hormone release in the dog. Acta Endocrinol. 82: 71–91, 1976PubMedGoogle Scholar
  15. [15]
    Panerai A.E., Salerno E., Manneschi M., Cocchi D., Muller E.E.:Growth hormone and prolactin responses to thyrotropin releasing hormone in patients with severe liver disease. J. Clin. Endocrin. Metabol. 45: 134–140, 1977CrossRefGoogle Scholar
  16. [16]
    Sicuteri F., Anselmi B., Del Bianco P.:5-hydroxy-tryptamine supersensitivity as a new theory of headache and central pain: a clinical pharmacological approach with p-chlorophenyl-alanine. Psychopharmacologia 29: 347–356, 1973PubMedGoogle Scholar
  17. [17]
    Sicuteri F.:Natural opioids in migraine. In Adv. Neurol. Vol. 33, edited by M. Critchley et al., Raven Press, New York, 1982Google Scholar
  18. [18]
    Sicuteri F., Anselmi B., Fanciullacci M.:The serotonin (5-HT) theory of migraine. Adv. Neurol. 4: 383–394, 1974Google Scholar
  19. [19]
    Spampinato S., Locatelli V., Cocchi D., Vicentini L., Bajusz S., Ferri G., Muller E.E.:Involvement of brain serotonin in the prolactin release effect of opioid peptides. Endocrinology 105: 163–170, 1979PubMedGoogle Scholar
  20. [20]
    Truesan E.M., Enbanks E.E., Jakobs B.L.:Behavioral evidence for supersensitivity following destruction of central serotoninergic nerve terminals by 5,7-dihydroxy-tryptamine. J. Pharmacol. Exp. Ther. 198: 23–32, 1976PubMedGoogle Scholar

Copyright information

© Masson Italia Periodici S.r.l. 1984

Authors and Affiliations

  • Bussone G. 
    • 1
  • Boiardi A. 
    • 1
  • Mantia L. La 
    • 1
  • Frediani F. 
    • 1
  • Martini A. 
    • 1
    • 2
  • Giulio A. M. Di 
    • 1
    • 2
  • Panerai A. E. 
    • 1
    • 2
  1. 1.Centro Cefalee Istituto Neurologico “C. Besta”Milano
  2. 2.Istituto di farmacologiaScuola di medicina, UniversitàMilano

Personalised recommendations